Interferon alpha-2b treatment in an HIV-infected patient with hepatitis B virus induced nephrotic syndrome.
A 31-year-old male patient with an asymptomatic HIV infection but with a hepatitis B (HBV) related membraneous glomerulonephritis with nephrotic syndrome was given interferon alpha-2b subcutaneously 3 times weekly for 7.5 months. Zidovudine was added at the 10th week due to low CD4+ cell counts. Before the 6th week of treatment the patient reported a reduced need for diuretics to keep his lower limb edemas at a minimum. This response was partially sustained even after the 7.5 months interferon treatment course. The titers of HBV-DNA decreased markedly during the treatment with interferon but rose to pretreatment levels after discontinuation of the interferon treatment. The serum albumin increased but the proteinuria and hematuria were unaffected. Adverse reactions like fever, myalgias and anemia were tolerable and did not require dose reduction of either interferon or zidovudine. This treatment regimen, at least temporarily, improved the situation for the patient and can be worthwhile to try in HIV-infected patients with HBV related nephritis with nephrotic syndrome.
Lidman
C
C
Department of Infectious Diseases, Huddinge Hospital, Karolinska Institute, Stockholm, Sweden.
Magnius
L
L
Norder
H
H
Weiland
O
O
D000328:Adult; D004279:DNA, Viral / Q000097:blood; D015433:Glomerulonephritis, Membranous / Q000209:etiology / Q000628:therapy; D015658:HIV Infections / Q000150:complications*; D006509:Hepatitis B / Q000150:complications / Q000382:microbiology / Q000628:therapy*; D006515:Hepatitis B virus / Q000302:isolation & purification; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D009404:Nephrotic Syndrome / Q000209:etiology / Q000628:therapy*; D011994:Recombinant Proteins
D004279:DNA, Viral; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins